Riding the Cell and Gene Therapy Regulatory Tailwind: Business Model Innovations for the Next Decade

JUL 17, 2025

Disclaimer: The thoughts and opinions expressed in this essay are my own and do not the views or positions of my employer.

Table of Contents

Abstract

The Centers for Medicare & Medicaid Services (CMS) Cell and Gene Therapy (C Access Model represents a transformative regulatory development that creates unprecedented opportunities for health technology entrepreneurs. With 33 state participating and covering approximately 84% of Medicaid beneficiaries with sic cell disease, this initiative establishes a new framework for outcomes-based

agreements that addresses the fundamental challenge of high-cost, potentially curative therapies.

Key findings include:

- The CGT market is projected to reach $117.46 billion by 2034, growing at 1 CAGR
- CMS is pioneering federal-level outcomes-based agreements, creating standardized access policies across multiple states
- Significant gaps exist in data infrastructure, patient support services, and ri management tools
- Business opportunities span from technology platforms to specialized servic providers
- The model's success will likely expand to other therapeutic areas beyond sic cell disease

This analysis identifies specific business model innovations that can capitalize o regulatory tailwind while addressing critical market needs.

Introduction: The CGT Access Model as Market Catalyst

The landscape of cell and gene therapy access is undergoing a fundamental transformation. The CMS Cell and Gene Therapy Access Model, which began implementation in early 2025, represents the most significant regulatory innovat high-cost therapeutic access since the inception of the Medicaid Drug Rebate Program. This voluntary model enables CMS to negotiate outcomes-based agree on behalf of participating states, fundamentally altering the risk-sharing dynam between manufacturers, payers, and patients.

The model's initial focus on sickle cell disease serves as a proof-of-concept for a broader transformation in how the healthcare system approaches potentially cur but prohibitively expensive therapies. With gene therapies like Casgevy and Lyf

carrying price tags exceeding $2 million per patient, traditional reimbursement models have proven inadequate. The CGT Access Model addresses this challeng creating a framework where manufacturers accept financial risk tied to clinical outcomes, while states receive guaranteed access to standardized coverage polici

This regulatory development creates a tailwind effect that extends far beyond th immediate participants. The model establishes precedents for outcomes-based contracting, creates new data requirements, and generates demand for supportir infrastructure that did not previously exist. For health technology entrepreneurs represents a unique opportunity to build businesses that serve emerging market while riding the momentum of regulatory innovation.

The Regulatory Environment: Understanding the Tailwind

The CGT Access Model operates within a complex regulatory framework that cr both opportunities and constraints for entrepreneurs. The model's structure inv CMS negotiating key terms with manufacturers, including pricing that reflects rebates, outcome measures, and patient access policies. Participating states then decide whether to adopt these negotiated contracts, creating a quasi-federal app to what has traditionally been a state-by-state process.

The regulatory framework establishes several key precedents that extend beyonc immediate scope of sickle cell disease. First, it legitimizes outcomes-based agreements at the federal level, addressing longstanding concerns about Medica best price policies that have historically discouraged such arrangements. The mc includes specific provisions for rebates tied to clinical outcomes, creating a regu safe harbor that could influence broader adoption of value-based contracting.

Second, the model requires participating states to implement standardized acces policies, effectively creating a multi-state formulary approach for covered therap This standardization reduces administrative burden for manufacturers while en consistent patient access across jurisdictions. The implications extend beyond

individual therapies to the broader principle of coordinated coverage decisions a state lines.

Third, the model incorporates comprehensive patient support services, includin fertility preservation, travel expenses, case management, and behavioral health services. This holistic approach recognizes that successful gene therapy deploym requires infrastructure beyond the therapy itself. The regulatory framework thu creates demand for integrated service delivery models that address the complete patient journey.

The model's 11-year duration provides sufficient time for outcome measurement while creating predictable market conditions for investment and business development. This extended timeframe allows for the development of sophistica data collection and analysis capabilities that can inform future regulatory decisi and market opportunities.

The Economic Landscape: Market Opportunity and Constraints

The economic context surrounding the CGT Access Model reveals both the magnitude of opportunity and the constraints that shape business model innova The global cell and gene therapy market, valued at $21.28 billion in 2024, is proj to reach $117.46 billion by 2034, representing a compound annual growth rate o 18.7%. This growth trajectory reflects both increasing therapeutic approvals and expanding patient populations.

Within this broader market, the North American region accounts for approxima 49.75% of revenue, with the United States representing the largest single market $9.97 billion in 2024. The concentration of activity in the United States, combin with the fragmented nature of state-based Medicaid programs, creates unique challenges that the CGT Access Model addresses through standardization and fe coordination.

The economic model underlying gene therapies presents both opportunities and constraints for entrepreneurs. These therapies command premium pricing due t their potential for one-time curative treatment, with approved therapies ranging hundreds of thousands to millions of dollars per patient. However, this pricing r creates affordability challenges that limit market penetration and create demanc innovative financing and risk-sharing mechanisms.

The CGT Access Model addresses these economic constraints by shifting financ risk from payers to manufacturers while providing states with guaranteed access therapies. This risk reallocation creates opportunities for intermediary services can help manage and mitigate the financial exposure inherent in outcomes-based agreements. The model's provision for supplemental rebates tied to clinical outc creates a new category of financial instruments that require specialized expertise structure and manage.

Current data suggests that only 4 of 25 FDA-approved cell and gene therapies ha publicly identifiable outcomes-based agreements in place, indicating significant for growth in this market segment. The CGT Access Model's federal coordinatic approach has the potential to accelerate adoption by reducing transaction costs a standardizing contract terms across multiple states.

The economic landscape also reflects significant investment in research and development, with over 1,500 ongoing clinical trials registered with ClinicalTria This robust pipeline suggests continued growth in therapy approvals, creating ongoing demand for the infrastructure and services that support outcomes-based contracting.

Business Model Innovation Opportuniti

The CGT Access Model creates multiple categories of business opportunities th align with the specific needs generated by outcomes-based contracting and coordinated access policies. These opportunities span technology platforms, serv providers, and specialized intermediaries that can capture value from the regula tailwind.

Data Infrastructure and Analytics Platforms represent the most immediate opportunity for technology entrepreneurs. The model requires comprehensive d collection and reconciliation capabilities to support outcomes-based agreements across multiple states and manufacturers. Current healthcare data infrastructur inadequate for the real-time outcome tracking and financial reconciliation requi by these arrangements. Entrepreneurs can develop platforms that integrate clini data from multiple sources, apply artificial intelligence for outcome prediction, provide automated reconciliation of financial obligations based on clinical resul

The technical requirements for such platforms are substantial. They must integ with existing electronic health record systems, state Medicaid management information systems, and manufacturer databases while ensuring compliance wi privacy regulations and security requirements. The platforms must also support complex outcome measures that may involve multiple time points and different t of clinical endpoints. Success in this category requires deep expertise in healthc data integration, regulatory compliance, and financial systems.

Patient Support Service Platforms represent another significant opportunity. Th CGT Access Model explicitly includes coverage for fertility preservation, travel expenses, case management, and behavioral health services. Current healthcare infrastructure is poorly equipped to coordinate these diverse services across mul providers and geographic locations. Entrepreneurs can develop comprehensive p support platforms that coordinate the entire patient journey from initial diagno through long-term follow-up care.

These platforms must address unique challenges associated with gene therapy administration, including the need for specialized treatment centers, extended inpatient stays, and complex preparatory procedures. The platforms must also navigate the intersection of medical services, travel logistics, and behavioral hea support while maintaining cost-effectiveness and quality outcomes. Success requ expertise in care coordination, logistics management, and patient engagement technologies.

Risk Management and Insurance Products offer opportunities for entrepreneurs expertise in actuarial science and healthcare finance. The outcomes-based agreer create new categories of financial risk that require specialized insurance produc risk management services. Manufacturers participating in the model face potent liability for therapy failures, while states assume responsibility for patient acces outcome reporting. Entrepreneurs can develop insurance products that protect against these risks while providing actuarial services that support pricing and contract negotiation.

The development of these products requires sophisticated modeling of therapy success rates, patient population characteristics, and healthcare utilization patte The products must also account for the long-term nature of gene therapy outcor which may not be fully apparent for years after treatment. Success in this catego requires expertise in healthcare actuarial science, insurance product developmer and regulatory compliance.

Clinical Trial and Real-World Evidence Platforms represent opportunities for entrepreneurs focused on the research and development aspects of gene therapy. CGT Access Model creates demand for robust outcome measurement and real-w evidence generation capabilities that can support both regulatory requirements commercial contracting. Entrepreneurs can develop platforms that streamline cl trial conduct, enhance real-world evidence collection, and provide predictive an for therapy outcomes.

These platforms must address the unique challenges of gene therapy research, including small patient populations, long-term follow-up requirements, and con outcome measures. The platforms must also support the translation of clinical tr data into real-world evidence that can inform outcomes-based contracting decis Success requires expertise in clinical research, biostatistics, and healthcare analy

Provider Network and Specialty Care Platforms address the infrastructure requirements for gene therapy delivery. The model requires participating states contract with specialized providers, including out-of-state facilities when necess This creates opportunities for entrepreneurs to develop platforms that facilitate

provider network management, credentialing, and care coordination across state The platforms must address the unique requirements of gene therapy centers, including specialized equipment, trained personnel, and quality assurance protc

Financial Services and Payment Platforms represent opportunities for entrepren with expertise in healthcare finance and payment systems. The outcomes-based agreements create new categories of financial transactions that require specializ payment processing and reconciliation capabilities. Entrepreneurs can develop platforms that facilitate the complex financial flows between manufacturers, sta and healthcare providers while ensuring compliance with regulatory requiremer and audit trails.

Risk Mitigation and Strategic Considerations

The business opportunities created by the CGT Access Model come with signifi risks that entrepreneurs must carefully evaluate and mitigate. The regulatory na of the opportunity creates both advantages and vulnerabilities that require strat planning and risk management.

Regulatory risk represents the primary concern for entrepreneurs building busi dependent on the CGT Access Model. The model is voluntary for both states an manufacturers, creating uncertainty about long-term participation rates and ma size. While 33 states have initially committed to participation, covering 84% of Medicaid beneficiaries with sickle cell disease, future participation depends on model's success in achieving its stated goals of improving access, health outcom and cost-effectiveness.

The model's 11-year duration provides some stability, but regulatory changes at federal or state level could significantly impact business opportunities. Entrepre must develop business models that can adapt to changing regulatory environmer while maintaining core value propositions. This requires careful monitoring of regulatory developments, strong relationships with key stakeholders, and flexibl technology architectures that can accommodate changing requirements.

Market concentration risk emerges from the model's initial focus on sickle cell disease and limited number of participating manufacturers. The current model includes only two manufacturers, bluebird bio and Vertex Pharmaceuticals, crea dependency on a small number of commercial relationships. Entrepreneurs mus assess the sustainability of business models that depend on continued participat these manufacturers and the likelihood of expansion to additional therapeutic a

The model's expansion to other therapeutic areas depends on its success in the s cell disease pilot, creating uncertainty about future market size and growth opportunities. Entrepreneurs should develop expansion strategies that can lever initial investments in sickle cell disease infrastructure for broader therapeutic applications while maintaining flexibility to pivot if the model's scope changes.

Technology risk is particularly relevant for entrepreneurs developing data infrastructure and analytics platforms. The model's success depends on the abili collect, integrate, and analyze complex clinical and financial data across multipl stakeholders and systems. Current healthcare data infrastructure is fragmented often incompatible, creating significant technical challenges for platform development.

Entrepreneurs must invest in robust data integration capabilities while anticipa continued evolution in healthcare information systems and regulatory requirem This requires significant upfront investment in technology development and ong maintenance costs that may not be immediately offset by revenue generation. Su depends on the ability to achieve scale quickly while maintaining high levels of quality and system reliability.

Competitive risk emerges from the attractiveness of the market opportunity and likelihood of competition from established healthcare technology companies. La electronic health record vendors, healthcare consulting firms, and pharmaceutic services companies have existing capabilities and customer relationships that co leveraged to compete in the CGT Access Model ecosystem.

Entrepreneurs must develop defensible competitive advantages that can withsta competition from larger, better-resourced competitors. This typically requires fo on specialized expertise, innovative technology approaches, or unique customer relationships that are difficult to replicate. Success also depends on the ability to establish market presence quickly before larger competitors recognize and respo the opportunity.

Financial risk is inherent in the outcomes-based contracting model, which ties revenue to therapy success rates and patient outcomes. Entrepreneurs developin management products or platforms that assume financial exposure must carefull model potential losses and maintain adequate capital reserves. The long-term na of gene therapy outcomes creates additional uncertainty about the timing and magnitude of financial obligations.

Implementation Roadmap and Market Entry Strategies

Successful market entry in the CGT Access Model ecosystem requires careful ti strategic partnerships, and phased implementation approaches that align with th model's rollout timeline and regulatory requirements. The model's January 2025 January 2026 implementation window creates both opportunities and constraint entrepreneurs seeking to establish market presence.

The initial phase of market entry should focus on establishing relationships witl stakeholders and developing minimum viable products that address immediate market needs. States participating in the model face implementation challenges including reimbursement system changes, coverage policy alignment, and provic network management. Entrepreneurs can provide immediate value by addressing these implementation challenges while building long-term platform capabilities

Partnership strategies are critical for market entry success. Entrepreneurs shoul identify potential partners among participating states, manufacturers, healthcar providers, and technology vendors who can provide market access, technical exp and customer validation. The model's emphasis on standardization creates

opportunities for partnerships that can scale solutions across multiple states and stakeholders.

State Medicaid agencies represent key partnership opportunities for entrepreneurs focused on data infrastructure and patient support services. These agencies face significant implementation challenges and have limited internal expertise in outcomes-based contracting and gene therapy management. Entrepreneurs can provide value by offering specialized expertise and technology solutions while building long-term relationships that can extend to other therapeutic areas.

Manufacturer partnerships offer opportunities for entrepreneurs developing risk management and clinical evidence platforms. Manufacturers participating in the model assume significant financial risk and require sophisticated capabilities for outcome measurement, financial reconciliation, and patient support. Entrepreneurs can provide specialized services that help manufacturers manage these risks while improving their competitive position in the market.

Healthcare provider partnerships are essential for entrepreneurs developing patient support and care coordination platforms. Gene therapy centers and specialized providers face unique challenges in delivering complex treatments while managing costs and outcomes. Entrepreneurs can provide value by streamlining care delivery processes, improving patient outcomes, and reducing administrative burden.

Technology development strategies should prioritize interoperability and scalability from the initial design phase. The model's multi-state, multi-manufacturer structure requires platforms that can integrate with diverse systems and scale to accommodate growth. Entrepreneurs should invest in modern cloud-based architectures, standardized data formats, and API-based integration capabilities that can support future expansion.

Regulatory compliance strategies must address the complex intersection of federal and state regulations governing Medicaid, healthcare data, and pharmaceutical contracting. Entrepreneurs should invest in legal expertise and compliance capabilities early in the development process to avoid costly redesigns and regul

delays. The model's regulatory framework creates both opportunities and constr that must be carefully navigated.

Funding strategies should align with the model's long-term development timelir the significant upfront investment required for platform development and mark entry. Traditional venture capital funding may be appropriate for technology pla development, while specialized healthcare investors may be better suited for ser based business models. Entrepreneurs should also consider strategic investment potential partners or customers who can provide both capital and market access

Market expansion strategies should anticipate the model's potential extension tc therapeutic areas and geographic markets. The model's success in sickle cell dis will likely lead to expansion to other high-cost, potentially curative therapies. Entrepreneurs should develop capabilities that can be leveraged across multiple therapeutic areas while maintaining focus on current market opportunities.

Conclusion: The Future of Health Tech the CGT Era

The CMS Cell and Gene Therapy Access Model represents more than a regulato innovation; it signals a fundamental shift in how the healthcare system approach high-cost, potentially curative therapies. This transformation creates unprecede opportunities for health technology entrepreneurs who can navigate the comple intersection of regulatory requirements, clinical outcomes, and financial risk management.

The model's success in addressing the access challenges associated with gene therapies for sickle cell disease will likely catalyze broader adoption of outcome based contracting and coordinated access policies across multiple therapeutic ar This expansion creates a sustainable foundation for businesses that can demonst value in the initial implementation while building capabilities for future growth

The regulatory tailwind created by the CGT Access Model extends beyond the immediate participants to influence broader healthcare policy and market dynar

The model's emphasis on standardization, outcome measurement, and risk shari aligns with broader trends toward value-based healthcare and precision medicin Entrepreneurs who can position their businesses at the intersection of these tren will be well-positioned for long-term success.

The technical and operational challenges created by the model require specializ expertise and significant investment in infrastructure development. However, th barriers to entry also create opportunities for entrepreneurs who can successfull navigate the complexity while delivering demonstrable value to stakeholders. Th model's long-term nature provides sufficient time for business development and market validation while creating predictable revenue opportunities for successfu participants.

The ultimate success of businesses built around the CGT Access Model depends the model's ability to achieve its stated goals of improving access, health outcom and cost-effectiveness. Early indicators suggest strong stakeholder commitment reasonable prospects for success, but entrepreneurs must remain adaptable to changing market conditions and regulatory requirements.

The transformation of cell and gene therapy access represents one of the most significant opportunities in healthcare technology in the past decade. Entrepren who can successfully navigate the regulatory environment, build robust technolo platforms, and deliver measurable value to stakeholders will be positioned to cap significant returns while contributing to improved patient outcomes and healthc system sustainability.

The CGT Access Model creates a template for addressing the access challenges associated with high-cost, potentially curative therapies. As gene and cell therap continue to advance and receive regulatory approval, the need for sophisticated infrastructure and support services will only grow. Entrepreneurs who establish successful businesses in the current market will be well-positioned to benefit fr this continued expansion while contributing to the broader transformation of healthcare delivery and financing.

The convergence of regulatory innovation, technological advancement, and mark demand creates a unique opportunity for entrepreneurs to build businesses that thrive in the evolving healthcare landscape. The CGT Access Model provides a roadmap for success while creating immediate opportunities for value creation a market entry. For health technology entrepreneurs, the time to act is now.

1 Like

← Previous

Nex

Discussion about this post

Comments | Restacks

Write a comment...

Christopher Pilkington Christopher Pilkington Jul 17, 2025

Great summary Trey

LIKE REPLY